Year: 2025

Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, localized prostate cancer Recently announced positive final data from randomized controlled phase 2a clinical trial of CAN-2409 in borderline resectable pancreatic ductal adenocarcinoma On track to report biomarker and final overall survival data from open label phase 2a clinical trial per protocol analysis in non-small cell lung cancer (NSCLC) patients who received two administrations of CAN-2409, expected in Q1 2025 On track to report biomarker and initial survival data from ongoing phase 1b trial evaluating multiple doses of CAN-3110 in patients with recurrent high-grade glioma (rHGG), expected in Q4 2025  Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway,...

Southlake, TX, March 13, 2025 (GLOBE NEWSWIRE) — HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (“AI”)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the third quarter fiscal 2025 ended January 31, 2025 and provided a business update. Third Fiscal Quarter 2025 Highlights: During the third quarter of fiscal year 2025 (“Q3 FY2025”) and to date in 2025, HeartSciences has seen material progress towards FDA submissions of our products and there have been significant positive developments in the AI-ECG field. A summary of the current status and key business highlights for Q3 FY2025 include:AI-ECG presents a generational opportunity to modernize...

– Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition – – Cash, cash equivalents and marketable securities as of December 31, 2024 of $316.9 million, with cash runway expected into at least Q4 2026, excluding anticipated milestones from existing collaborations – – Conference call today at 2:00 p.m. PT / 5:00 p.m. ET – SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) — Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the full year 2024 and recent business highlights. The Company also announced the completion of a strategic portfolio review resulting in...

IRVINE, Calif., March 13, 2025 (GLOBE NEWSWIRE) — Shimmick Corp. (NASDAQ: SHIM), a leading water infrastructure company, today announced financial results for the fourth quarter and fiscal year ended January 3, 2025. HighlightsReported revenue of $104 million, which includes $80 million of Shimmick Projects revenue, for Q4 2024, and revenue of $480 million, which includes $356 million of Shimmick Projects revenue, for FY2024 Reported liquidity of $100 million as of January 3, 2025, reflecting the positive outcomes of the Transformation Plan implemented in 2024. Further and on March 12, 2025, we entered into a new credit agreement which replaced the MidCap Revolving Credit Facility and provides a total commitment of $15 million. Recognized a net loss of $38 million and Adjusted EBITDA of $(27) million for Q4 2024, largely attributable...

–  Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases –  Lead target and indication to be announced MY 2025 –  Cash balance of $185.2 million expected to fund operations into 2H 2027 CAMBRIDGE, MASS., March 13, 2025 (GLOBE NEWSWIRE) — Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, reported business highlights and fourth quarter and full year 2024 financial results. “Our T cell-selective lipid nanoparticle (LNP) is designed to overcome a long-standing challenge for siRNA therapeutics, which is to reach T cells while sparing broader immune cells and achieve potent knockdown of genetic targets in vivo,” said Geoff McDonough, M.D., chief...

LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) —  ServiceTitan, Inc. (NASDAQ: TTAN), the software platform that powers the trades, today announced financial results for the fiscal fourth quarter and full fiscal year ended January 31, 2025. “The beginning of the new public market era for the trades, for our customers, and for ServiceTitan is off to a good start,” said Ara Mahdessian, co-founder and CEO. “I am proud of the way Titans executed this quarter to cap off a transformative year for our business. We plan to carry this same focused execution into fiscal year 2026.” “Our goal and growth strategy is to become the operating system for the trades,” said Vahe Kuzoyan, co-founder and President. “Our core residential trades are performing well while our investments in roofing and commercial continue to deliver.” Fourth Quarter Fiscal...

BELGRADE, Mont., March 13, 2025 (GLOBE NEWSWIRE) — Bridger Aerospace Group Holdings, Inc. (“Bridger”, “the Company” or “Bridger Aerospace”), (NASDAQ: BAER, BAERW), one of the nation’s largest aerial firefighting companies, today reported record results for the fourth quarter and year ended December 31, 2024. Highlights:Record revenue of $98.6 million for 2024 and $15.6 million in the fourth quarter with multiple Super Scoopers and surveillance aircraft flying into November after an early start to the 2024 wildfire season Earliest deployment of Super Scoopers in January 2025 to the Palisades Fire and current deployment of MMA aircraft and Super Scoopers to Oklahoma, reinforcing the trend of year-round wildfire activity 80% improvement in net loss to $15.6 million in 2024 compared to 2023 Doubling of Adjusted EBITDA to $37.3 million...

DENVER, March 13, 2025 (GLOBE NEWSWIRE) — EverCommerce Inc. (“EverCommerce” or the “Company”) (NASDAQ: EVCM), a leading service commerce platform, today announced financial results for the quarter and year ended December 31, 2024. Fourth Quarter 2024 Financial HighlightsRevenue of $175.0 million, an increase of 3.3% compared to $169.4 million for the quarter ended December 31, 2023. Pro forma revenue, which excludes fitness solutions, increased approximately 7.0% compared to $163.6 million for the quarter ended December 31, 2023. Subscription and transaction fee revenue of $139.0 million, an increase of 4.2% compared to $133.5 million for the quarter ended December 31, 2023. Pro forma subscription and transaction fee revenue, which excludes fitness solutions, increased approximately 8.9% compared to $127.7...

Maroussi, Greece, March 13, 2025 – Pyxis Tankers Inc. (Nasdaq Cap Mkts: PXS), (the “Company” or “Pyxis Tankers”), an international shipping company, today announced unaudited results for the three months and year ended December 31, 2024. For the three months ended December 31, 2024, our revenues, net were $12.0 million. For the same period, our time charter equivalent (“TCE”) revenues were $7.9 million, a decrease of $4.0 million, or 33.6%, over the comparable period in 2023. Our Adjusted net income for the fourth quarter, 2024 was $0.3 million with Adjusted income per common share of $0.03 basic and diluted. Our Adjusted EBITDA for the three months ended December 31, 2024, was $3.3 million, a decrease of $4.5 million over the comparable period in 2023. On October 20, 2024, the Company fully redeemed all the remaining outstanding 303,171...

– Grew revenue from continuing operations 10% annually and 14% quarterly compared to the same period in 2023 – – Increased system-wide sales 9% for both the year and Q4 2024 – SCOTTSDALE, Ariz., March 13, 2025 (GLOBE NEWSWIRE) — The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of chiropractic clinics, reported its financial results for the quarter ended December 31, 2024. The results of operations of the corporate clinics business segment have been classified as discontinued operations for all periods presented, and the following figures represent continuing operations unless otherwise stated. Q4 2024 Financial HighlightsGrew revenue to $14.4 million, up 14% compared to Q4 2023. Reported net income from continuing operations of $986,000, compared to net loss from continuing operations...